Exciting developments in the biotech industry are paving the way for new treatments targeting high cholesterol. Recent studies presented at the American College of Cardiology Scientific Session have shown promising results for ANGPTL3-targeting drugs developed by Eli Lilly and Jiangsu Hengrui Pharmaceuticals. Eli Lilly’s solbinsiran, a small interfering RNA therapy, demonstrated significant reductions in apolipoprotein B levels, a key player in lipid metabolism, among patients with mixed dyslipidemia. Similarly, Jiangsu Hengrui Pharmaceuticals’ monoclonal antibody SHR-1918 displayed effectiveness in lowering LDL, triglycerides, and other lipids in patients with suboptimally treated hyperlipidemia.
These advancements in lipid metabolism therapies offer hope for individuals struggling with high cholesterol levels. With the potential for improved outcomes and better management of cardiovascular health, the development of ANGPTL3-targeting drugs signifies a significant step forward in biotech innovation. As these treatments continue to progress through clinical trials and regulatory processes, the future holds promise for more effective and targeted therapies for individuals with high cholesterol. The collaboration between biotech companies like Eli Lilly and Jiangsu Hengrui Pharmaceuticals showcases the industry’s commitment to addressing critical health issues and advancing medical solutions for better patient outcomes.
Read more from labiotech.eu
